Direct oral anticoagulants
Direct oral anticoagulants (DOACs) are a class of anticoagulant drugs used to prevent and treat thromboembolic disease.
Direct oral anticoagulants (DOACs) are a class of anticoagulant drugs used to prevent and treat thromboembolic disease. They are termed “direct” because they inhibit specific coagulation factors rather than broadly suppressing multiple steps in the clotting cascade. The main pharmacologic targets of this class are thrombin (factor IIa) and factor Xa, and this targeted mechanism has helped make DOACs a major alternative to warfarin in contemporary antithrombotic care.
Clinically, DOACs are widely used for stroke prevention in atrial fibrillation and for treatment or prevention of venous thromboembolism, and they are increasingly described as a cornerstone of thromboembolic prevention in patients with atrial fibrillation, venous thromboembolism, and other cardiovascular conditions. Compared with warfarin, they are often discussed in terms of more predictable anticoagulant effect and simpler use, while ongoing research continues to evaluate safety, bleeding risk, and performance in specific patient populations.
Where the papers sit
12 papers from the last 6 months study direct oral anticoagulants directly · updated from PubMed 1 Nov 2026
Study type 3 clinical trials · 4 observational · 4 human data · 1 unclassified
Themes 3 themes
-
DOAC Risks in Complex Care
DOAC decisions are moving toward individualized balancing of thromboembolism and bleeding in elderly, cancer, and post-traumatic intracranial hemorrhage populations. Studies focus on when treatment can safely resume after subdural or other intracranial bleeding, compared with warfarin and untreated risk. Drug removal before lupus anticoagulant testing is emerging as a practical way to reduce assay interference. Gastrointestinal bleeding and possible acute interstitial lung disease remain important safety signals requiring clarification.
6 papers · 50%
-
Atrial Fibrillation Stroke Prevention
Anticoagulation is being refined around stroke risk, treatment timing, and patient preferences in atrial fibrillation. Adherence measurement and standardized implementation are recurring priorities, especially after ischemic stroke. Protocols address when to start anticoagulation after emergency endovascular therapy while limiting hemorrhagic complications. The field is moving toward patient-centered decisions that integrate ischemic stroke, systemic embolism, bleeding, and medication-taking behavior.
4 papers · 33.3%
-
DOAC Safety Monitoring
Calcineurin inhibitors such as cyclosporine remain a key interaction concern when edoxaban, apixaban, or rivaroxaban are used after transplantation. Attention is shifting toward drug-specific exposure assessment rather than generic anticoagulant monitoring. Multiple LMWH-calibrated anti-Xa assays may support reagent-specific safety cutoffs. The main need is validated interpretation of anti-Xa results in patients with interacting therapies.
2 papers · 16.7%
Papers
The 12 papers from the last 6 months that study direct oral anticoagulants directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
DOAC Risks in Complex Care (6)
- Timing to restart direct oral anticoagulants after traumatic intracranial haemorrhage (RESTART tICrH): study protocol for a randomised controlled multicentre trial. BMJ open · 17 Sept 2026 PMID 42754280
- Pretest direct oral anticoagulant removal is highly effective in lupus anticoagulant testing while on direct oral anticoagulants: a real-life experience. Journal of thrombosis and haemostasis : JTH · 28 Aug 2026 PMID 42665229
- Direct oral anticoagulants in elderly patients with atrial fibrillation: a decade-long nationwide retrospective cohort study. BMJ open · 18 Aug 2026 PMID 42613109
- Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality. Cancer · 7 Jul 2026 PMID 42411384
- Direct oral anticoagulant resumption patterns after traumatic subdural hemorrhage in atrial fibrillation: A multicenter cohort study. Clinical neurology and neurosurgery · 22 Jun 2026 PMID 42330587
- Direct Oral Anticoagulant Consumption and the Risk of Acute Interstitial Lung Diseases: A Case-Crossover Study Using Japanese Administrative Data. Pharmacoepidemiology and drug safety · 23 May 2026 PMID 42175652
Atrial Fibrillation Stroke Prevention (4)
- Adherence to Anticoagulants in People with Stroke and Atrial Fibrillation: Implementation of Standardised Analytic Methods in Australia and Canada. International journal of stroke : official journal of the International Stroke Society · 10 Sept 2026 PMID 42717313
- Timing of anticoagulation after emergency endovascular therapy for acute ischaemic stroke with atrial fibrillation (TIMERS): protocol for a randomised controlled trial. BMJ open · 9 Sept 2026 PMID 42716680
- Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk. The New England journal of medicine · 28 Aug 2026 PMID 42663303
- Patient-Centered Evaluation of Anticoagulation in Atrial Fibrillation. NEJM evidence · 26 May 2026 PMID 42187550
DOAC Safety Monitoring (2)
- Direct oral anticoagulant use and drug-drug interactions in transplant recipients receiving calcineurin inhibitors. Journal of thrombosis and haemostasis : JTH · 7 Jul 2026 PMID 42413824
- Reagent-specific anti-Xa DOAC safety cutoffs can be established using multiple LMWH-calibrated anti-Xa assays. Clinical chemistry and laboratory medicine · 19 Jun 2026 PMID 42316297
By study type
Clinical trials (3)
- Timing to restart direct oral anticoagulants after traumatic intracranial haemorrhage (RESTART tICrH): study protocol for a randomised controlled multicentre trial. BMJ open · 17 Sept 2026 PMID 42754280
- Timing of anticoagulation after emergency endovascular therapy for acute ischaemic stroke with atrial fibrillation (TIMERS): protocol for a randomised controlled trial. BMJ open · 9 Sept 2026 PMID 42716680
- Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk. The New England journal of medicine · 28 Aug 2026 PMID 42663303
Observational studies and case reports (4)
- Direct oral anticoagulants in elderly patients with atrial fibrillation: a decade-long nationwide retrospective cohort study. BMJ open · 18 Aug 2026 PMID 42613109
- Direct oral anticoagulant use and drug-drug interactions in transplant recipients receiving calcineurin inhibitors. Journal of thrombosis and haemostasis : JTH · 7 Jul 2026 PMID 42413824
- Direct oral anticoagulant resumption patterns after traumatic subdural hemorrhage in atrial fibrillation: A multicenter cohort study. Clinical neurology and neurosurgery · 22 Jun 2026 PMID 42330587
- Direct Oral Anticoagulant Consumption and the Risk of Acute Interstitial Lung Diseases: A Case-Crossover Study Using Japanese Administrative Data. Pharmacoepidemiology and drug safety · 23 May 2026 PMID 42175652
Human data, design not indexed (4)
- Pretest direct oral anticoagulant removal is highly effective in lupus anticoagulant testing while on direct oral anticoagulants: a real-life experience. Journal of thrombosis and haemostasis : JTH · 28 Aug 2026 PMID 42665229
- Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality. Cancer · 7 Jul 2026 PMID 42411384
- Reagent-specific anti-Xa DOAC safety cutoffs can be established using multiple LMWH-calibrated anti-Xa assays. Clinical chemistry and laboratory medicine · 19 Jun 2026 PMID 42316297
- Patient-Centered Evaluation of Anticoagulation in Atrial Fibrillation. NEJM evidence · 26 May 2026 PMID 42187550
Unclassified: not yet indexed with MeSH (1)
- Adherence to Anticoagulants in People with Stroke and Atrial Fibrillation: Implementation of Standardised Analytic Methods in Australia and Canada. International journal of stroke : official journal of the International Stroke Society · 10 Sept 2026 PMID 42717313
Written from 12 PubMed abstracts, each one listed by PMID above. Published: 2026-06-24. Last written: 2026-08-20 by GPT. Drafted by language models from published abstracts; not medical advice.